BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

HeartWare (HTWR) Bails on Study Evaluating LVAD in Healthier Patients


10/18/2012 8:41:37 AM

HeartWare backs out of a study assessing its left-ventricular assist devices in a lower-risk heart failure population, a move that analysts say won't affect the company's efforts to win FDA approval for treating higher-risk patients. HeartWare International (NSDQ:HTWR) decided to back out of the REVIVE-IT study of its left-ventricular assist device, citing the need to focus efforts on the company's efforts to win FDA approval for the device. The REVIVE-IT study, which the HeartWare had contributed about $600,000 to, was designed to evaluate the company's LVAD system in patients with lower-risk heart disease. The decision to pull out of the study is "not too surprising," according to analysts at Leerink Swann. "Given the ongoing delay in REVIVE-IT protocol approval, it's not entirely surprising that the company has chosen to withdraw," analysts Danielle Antalffy and Robert Marcus wrote in a note to investors. "Because HTWR's HVAD is not yet approved in BTT or DT, our sense is that FDA may have been uncomfortable allowing investigators to proceed with a device that is not yet approved in current indications in this less-sick patient population."

Read at MassDevice

HeartWare
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES